Law B J, Laflèche J, Ahmadipour N, Anyoti H
Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Citizenship and Immigration Canada, Ottawa, ON.
Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):7-23. doi: 10.14745/ccdr.v40is3a02.
To describe the adverse event following immunization (AEFI) reporting profile for vaccines administered in Canada during 2012 and surveillance trends relative to reports for vaccines administered from 2005 through 2011.
Analysis of data based on AEFI reports received by the Public Health Agency of Canada by April 30, 2013, for vaccines marketed in Canada and administered from January 1, 2005, through December 31, 2012.
The AEFI reporting rate was 10.1 per 100,000 population in Canada for vaccines administered in 2012 and was inversely proportional to age. There was a trend of declining rates from 2005 (14.8) to 2012 overall and by age group. The vast majority of reports (94%-95%) were non-serious involving reactions at or near the vaccination site, rash and febrile events.
Canada has a strong pharmacovigilance system for vaccines with one of the highest AEFI reporting rates in developed countries. Vaccines marketed in Canada have a very good safety profile. This report enables comparisons across jurisdictions in Canada and globally.
描述2012年加拿大接种疫苗后的免疫接种不良事件（AEFI）报告情况，以及与2005年至2011年接种疫苗报告相比的监测趋势。
分析加拿大公共卫生局截至2013年4月30日收到的关于2005年1月1日至2012年12月31日在加拿大销售并接种的疫苗的AEFI报告数据。
2012年加拿大接种疫苗的AEFI报告率为每10万人10.1例，且与年龄成反比。总体上以及按年龄组划分，从2005年（14.8）到2012年报告率呈下降趋势。绝大多数报告（94%-95%）为非严重事件，包括接种部位或其附近的反应、皮疹和发热事件。
加拿大拥有强大的疫苗药物警戒系统，在发达国家中AEFI报告率最高之一。在加拿大销售的疫苗安全性良好。本报告有助于加拿大各辖区之间以及全球范围内的比较。
